ImmunoGen, Inc.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase…
Biotechnology
US, Waltham [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -93.26 | 131.57 | -1950.78 | |
| Graham Fair Price | 163.62 | 2.17 | 0.82 | |
| PEG | 98.42 | -0.05 | -3.25 | |
| Price/Book | -19.76 | 8.13 | 10.13 | |
| Price/Cash Flow | 4232.35 | 3223.20 | -74.40 | |
| Prices/Earnings | -87.32 | 37.11 | -292.56 | |
| Price/Sales | -32.69 | 40.24 | 59.78 | |
| Price/FCF | 4232.35 | 3223.20 | -74.40 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -0.82 | 0.98 | 0.99 | |
| Operating Margin | 354.25 | 0.23 | -0.05 | |
| ROA | 528.93 | 0.04 | < 0.005 | |
| ROE | < 0.005 | 0.05 | 532.63 | |
| ROIC | < 0.005 | 0.04 | 381.05 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | < 0.005 | 4.05 | -99.95 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 0.90 | 7.20 | 698.53 | |
| EPS QOQ | 0.90 | 7.21 | 701.80 | |
| FCF QOQ | 0.10 | 1.02 | 961.96 | |
| Revenue QOQ | 0.67 | 0.36 | -45.45 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Positive
Fundamentals
Leverage & Liquidity
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 320.10 | 229.49 | -28.31 | |
| Days Sales Outstanding (DSO) | 86.55 | 103.70 | 19.82 | |
| Inventory Turnover | 0.28 | 0.39 | 39.48 | |
| Debt/Capitalization | 0.13 | 0.08 | -42.30 | |
| Quick Ratio | 6.96 | 5.47 | -21.42 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q2 | Q3 | Δ in % | |
|---|---|---|---|---|
| Book Value | 1.86 | 1.95 | 4.81 | |
| Cash | 2.17 | 2.11 | -3.02 | |
| Capex | < 0.005 | < 0.005 | -1490.16 | |
| Free Cash Flow | -0.25 | < 0.005 | -98.06 | |
| Revenue | 0.32 | 0.39 | 24.95 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad